Ed Seguine, chief executive officer of Clinical Ink, talks about how hybrid trials, bring your own device (BYOD) ePRO, and direct data capture (DDC) can provide a valuable solution during and following a healthcare crisis like COVID-19.
Clinical Ink is the leader in virtual and hybrid virtual trials. Implementing a virtual eSource platform wherever possible can ease operations and facilitate rapid, safety-conscious, cost-effective research. BYOD is an important tool for communicating with patients, capturing and sharing their inputs efficiently, and maintaining patient engagement for better adherence and retention throughout your trial.
Listen to the podcast to learn more.
